HIGHLIGHTS
- who: Thomas Welte from the Department of, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany have published the paper: Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study, in the Journal: (JOURNAL)
- what: Having observed no significant overrepresentation of eculizumab treatment in stable vs negative late outcomes, the authors aimed to analyze the effect of eculizumab in greater detail. This study has several limitations, the major being the retrospective character and the lack of standardized follow-up, and a heterogenous population with both native kidneys and kidney grafts, as well . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.